Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Jlabs
BioCentury | Oct 25, 2024
Finance
Why Rice is launching a venture studio in Houston’s emerging biotech ecosystem
Founders see chance to build start-ups from university IP, with clinical infrastructure already in place from local institutions
BioCentury | Jul 27, 2024
Management Tracks
Hartley to succeed Winkler as OnKure’s CSO
Plus: Patterson joins Zymeworks and updates from Stuart Therapeutics and JLABS
BioCentury | Sep 27, 2023
Discovery & Translation
Eyeing ‘fertile’ climate for biotechs, J&J building presence in Singapore
Pharma’s JLABS unit aims to help grow ecosystem by connecting translational projects with funding, management and other resources
BioCentury | Jun 29, 2023
Deals
Janssen says half pipeline value will come from outside
What the last two years of BD reveal about the kind of innovation J&J is seeking, and where it’s finding opportunities
BioCentury | May 16, 2023
Management Tracks
JLABS vet Calcagno becomes CBO of Vir
Plus: Therini names Frank Lee executive chair and updates from OMass, Sapir, Pan Cancer T, and more
BioCentury | Aug 29, 2022
Management Tracks
Executives say success in new era means re-learning leadership
Shaking up the C-suite with new skills, human and technical, will mean breaking a few eggs
BioCentury | Apr 13, 2022
Product Development
April 12 Quick Takes: FDA lifts clinical hold on magrolimab studies
Plus: Setback for Myovant at FDA and updates from Takeda, Ocugen, Prilenia, AbbVie and more
BioCentury | Feb 11, 2022
Deals
Feb. 10 Quick Takes: RA, Adjuvant ready Curevo to take on Shingrix with $60M A round
Seagen slides on guidance, and updates from Arkuda, Altesa, Aeglea, Congruence, 1859 and more
BioCentury | Dec 22, 2021
Management Tracks
BIO’s McMurry-Heath joining Bioventus board
Plus: OSE, Centogene and OncoHealth
BioCentury | Dec 8, 2021
Deals
Dec. 7 Quick Takes: Freenome raises $300M series D
Plus Apple Tree funds Crick Institute spinout, METiS launches, Flagship, Persephone and more
Items per page:
1 - 10 of 83